Low-dose antifungal prevention for patients with low white blood cell counts
Treatments studied
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy, Infections clinical trials.
This trial tests a low dose of an antifungal medicine (liposomal amphotericin B) to prevent fungal infections in patients whose white blood cell counts are very low for more than a week. It may help patients who are at high risk for fungal infections and cannot take other antifungal drugs.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have a condition or treatment that puts you at high risk for fungal infections, such as a stem cell transplant, certain blood cancers, or CAR T-cell therapy.
- Your white blood cell count is expected to be very low (below 0.5) for more than 7 days.
- You cannot take other antifungal medicines due to side effects or other reasons, and your doctor has already decided to start this preventive treatment.
- You do not have a current fungal infection, serious kidney or liver problems, or heart failure.
- You are not pregnant or breastfeeding, and if you could become pregnant, you agree to use contraception.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a low dose of an antifungal medicine (liposomal amphotericin B) to prevent serious fungal infections in children whose immune system is weak after cancer treatment or a stem cell transplant. It's for kids aged 3 to 17 who are at high risk for these infections.
This trial looks at how a specific antifungal medicine, called liposomal amphotericin B, given over a longer period, helps prevent serious fungal infections in people undergoing treatment for cancer or receiving a stem cell transplant. It may be an option if you are at high risk for these infections.
This trial tests whether using a targeted antifungal medicine (aimed at PTX3) can better prevent serious fungal infections in adults with AML or a related bone marrow disease who will have very low neutrophils. It may help lower the risk of dangerous infections during intensive chemotherapy hospital stays.
This study looks at how the body processes the antifungal medicine liposomal amphotericin B in people who are also having plasma exchange (a blood-filtering procedure). The goal is to understand if dosing needs to be adjusted when both treatments are used together.
This trial tests whether amphotericin B can treat new fungal infections that develop in people with blood cancers even after they have taken preventive antifungal medicine. It may help patients who have a confirmed or suspected fungal infection while on that prevention.
This study follows children and teens with blood cancers who got a fungal infection while on preventive antifungal medicine. It looks at how well liposomal amphotericin B (AmBisome) works and how safe it is for them.
Hear when a new Acute Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.